"Non-Alcoholic Steatohepatatis (NASH) is the progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD)with a prevalence of approximately 2% to 3% of the general population. Non-alcoholic steatohepatitis can lead to cirrhosis and its complications, hepatocellular carcinoma, and end stage liver disease. Non-alcoholic steatohepatitis is defined histologically as a multicomponent condition composed of hepatic steatosis, inflammation, and hepatocyte ballooning in varying proportions. NASH differs from steatosis alone by the presence of hepatic cell inflammation and injury in response to lipotoxic intermediates that are accumulated and metabolized in the steatotic liver. NASH is closely associated with metabolic risk factors including obesity, T2DM, and dyslipidemia. Pathophysiologically, NASH is frequently associated with a hyperinsulinemic or insulin resistant state, leading to adipose tissue dysfunction and increased hepatic de novo lipogenesis."

• A Phase IIa Study to assess Safety, Tolerability, and Pharmacodynamics of AZD4831 in Adult Participants with Non-cirrhotic NASH with Fibrosi … Ended
  2022-500594-13-00 4 2022-12-14

Showing 1–1 of 1 trials